These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16336486)

  • 1. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW.
    Pleil AM; Coyne KS; Reese PR; Jumadilova Z; Rovner ES; Kelleher CJ
    Value Health; 2005; 8 Suppl 1():S25-34. PubMed ID: 16336486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The responsiveness of the OAB-q among OAB patient subgroups.
    Coyne KS; Matza LS; Thompson C; Jumadilova Z; Bavendam T
    Neurourol Urodyn; 2007; 26(2):196-203. PubMed ID: 17016794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The responsiveness of the Overactive Bladder Questionnaire (OAB-q).
    Coyne KS; Matza LS; Thompson CL
    Qual Life Res; 2005 Apr; 14(3):849-55. PubMed ID: 16022077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the urgency perception scale.
    Cardozo L; Coyne KS; Versi E
    BJU Int; 2005 Mar; 95(4):591-6. PubMed ID: 15705086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.
    Homma Y; Uemura S
    BJU Int; 2004 May; 93(7):1009-13. PubMed ID: 15142153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ; Reese PR; Pleil AM; Okano GJ
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
    Coyne KS; Matza LS; Kopp Z; Abrams P
    Eur Urol; 2006 Jun; 49(6):1079-86. PubMed ID: 16460875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
    Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
    BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
    Colman S; Chapple C; Nitti V; Haag-Molkenteller C; Hastedt C; Massow U
    Urology; 2008 Oct; 72(4):803-7. PubMed ID: 18722655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.